
GNLX
Healthcare · Biotechnology · $84.4M market cap
$1.86-0.04 (-1.8%)Nov 13, 4:00 PM EST
Next report
Time not confirmed
Analyst consensus
Fiscal period ending Sep 30, 2026
EPS trend, 90 days to now · +2.5% over 90 days · 30-day revisions 2 up, 1 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 18, 2026 · upcoming | Time not confirmed | -0.20 | -0.21 | -5.0% |
| Aug 13, 2026 | After the close | -0.20 | -0.21 | -5.0% |
| May 7, 2026 | After the close | -0.20 | -0.20 | 0.0% |
| Mar 20, 2026 | Time not confirmed | -0.22 | -0.24 | -9.9% |
| Nov 5, 2025 | Time not confirmed | -0.23 | -0.21 | +8.7% |
| Aug 7, 2025 | Time not confirmed | -0.22 | -0.20 | +9.1% |
| May 6, 2025 | After the close | -0.24 | -0.21 | +12.5% |
| Mar 28, 2025 | Time not confirmed | -0.25 | -0.25 | 0.0% |
| Nov 14, 2024 | After the close | -0.19 | -0.19 | 0.0% |
| Aug 14, 2024 | After the close | -0.21 | -0.22 | -4.8% |
| May 9, 2024 | After the close | -0.21 | -0.29 | -38.1% |
| Mar 29, 2024 | After the close | -0.19 | -0.25 | -31.6% |
| Nov 14, 2023 | After the close | -0.15 |
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and…
| -0.20 |
| -33.3% |
| Aug 14, 2023 | Before the open | -0.15 | -0.23 | -53.3% |
| May 15, 2023 | Before the open | -0.16 | -0.53 | -231.3% |
| Mar 29, 2023 | After the close | 0.00 | -0.12 | — |
| Sep 19, 2022 | Time not confirmed | — | -0.12 | — |
| Jun 24, 2022 | Time not confirmed | — | -0.16 | — |